HAYWARD, Calif., March 29, 2024 ~ Dr. Li Ou, Vice President of Research at Avirmax Inc., will be taking on a significant role at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore from May 7th to 11th, 2024. As a current committee member of ASGCT and an established investigator in AAV gene therapy and gene editing, Dr. Ou will be chairing two scientific sessions during the conference.

The first session, titled "AAV Vectors - Capsid Engineering Session 1," will take place on Wednesday, May 8th at 3:45 PM. This session will focus on the fundamental scientific understanding of AAV vectors and their potential for gene therapy. Dr. Ou's expertise in this area makes him the perfect candidate to lead this discussion.

On Friday, May 10th at 8:00 AM, Dr. Ou will also chair the "2nd Annual 5-Minute Thesis Challenge." This session will feature short presentations from young researchers on their innovative ideas and research in the field of gene and cell therapy.

More on Marylandian

• U.S. Navy Returns to BEYA STEM Conference, Strengthening 40-Year Legacy of Military Recruitment and STEM Equity
• Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
• Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
• Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
• Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence

Dr. Ou joined Avirmax in July 2023 as Vice President of Research and has since been instrumental in expanding the company's research programs in capsid engineering and in vivo studies. He is a strong advocate for unlocking the full potential of AAV vectors and is dedicated to advancing translational development through collaboration with other institutions.

Prior to joining Avirmax, Dr. Ou was an Assistant Professor at the University of Minnesota where he led groundbreaking research on gene therapy for lysosomal diseases. His work resulted in two IND approvals from the FDA, showcasing his expertise and contributions to the field.

In addition to his role as session chair, Dr. Ou recently moderated an online webinar for ASGCT's Professional Development Café on February 16th. The webinar featured a talk on utilizing artificial intelligence in gene and cell manufacturing, further highlighting Dr. Ou's commitment to advancing the field of gene and cell therapy.

Attendees of the ASGCT annual meeting can also visit Avirmax at booth #818 to learn more about their latest AAV platform technologies. With Dr. Ou's leadership and expertise, Avirmax continues to make significant strides in the field of gene and cell therapy.

---

Show All News | Report Violation